Adverse events following Cannabis for medical use in Tuscany: an analysis of the Italian Phytovigilance database.
Despite a significant increase in using Cannabis for medical purposes, current evidence on its safety in real-world clinical practice is still poorly characterized. By a case-by-case analysis of spontaneous reports of suspected adverse events (AEs) collected in Tuscany within the Italian Phytovigilance database, the aim of the present study was to describe AEs occurred in patients exposed to medical Cannabis. We evaluated all reports of Cannabis-related suspected AEs collected within the Phytovigilance database until December 2018. Information regarding Cannabis therapy, patient's demographic and clinical characteristics, concomitant medications, AE description according to the Medical Dictionary for Regulatory Activities (MedDRA) classification, AE seriousness, and AE outcome, were collected. The causality assessment was performed following WHO-UMC criteria. Fifty-three Cannabis-related AE reports were analysed. The majority of patients were females (77.3%), with a mean age of 61.9 years. Thirty-nine (73.6%) cases were defined as non-serious and the majority of them (86.9%) showed a complete resolution or improvement. Forty-six (86.8%) cases were judged as probably related to Cannabis consumption. The most frequently reported SOC was psychiatric and nervous system disorders, and in 16 cases a potential drug-drug interaction was present. Cannabis was generally well tolerated and the majority of AEs were mild and transient. Our analysis highlighted important safety issues for clinical practice, in particular the need for an accurate prescription monitoring during the titration phase, particularly in presence of concomitant medications.